OncoAlert· @OncoAlert · X·· 14 小时前评分70
正文 · 机器翻译
#OncoAlertTOPTweet 第 3 天 #ESMO26
NEJM 发布的帖子
SAFFRON
在 osimertinib 治疗期间进展的 EGFR 突变、MET 阳性 NSCLC 中，与 platinum–pemetrexed 相比，加用 savolitinib 可显著改善无进展生存期和总生存期，且严重不良事件发生率相近。
呼叫我们的专家们
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
90 浏览 · 0 赞 · 0 转发 · 0 回复
Presented at #ESMO26: In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON trial results: https://nej.md/4hXdueb @myESMO在 X 查看被引用的帖子
来源：OncoAlert · x.com